Home » News » Drug Sponsors » Medivir to acquire BioPhausia

Medivir to acquire BioPhausia

Tuesday, April 12, 2011

Swedish pharmaceutical company Medivir will acquire BioPhausia, another Sweden-based firm, in a deal that will “create a platform” for its hepatitis C treatment, according to Pharma Times.

Medivir is offering a combination of cash and new shares, putting BioPhausia’s value at about $90 million.

Medvir says that BioPhausia will provide it with “complementary competencies in regulatory affairs, logistics, distribution, marketing, sales and quality assurance,” plus a presence across a part of the Nordic region.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!